JPWO2022051575A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022051575A5 JPWO2022051575A5 JP2023515155A JP2023515155A JPWO2022051575A5 JP WO2022051575 A5 JPWO2022051575 A5 JP WO2022051575A5 JP 2023515155 A JP2023515155 A JP 2023515155A JP 2023515155 A JP2023515155 A JP 2023515155A JP WO2022051575 A5 JPWO2022051575 A5 JP WO2022051575A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- acetylglucosamine
- derivative
- vitamin
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 20
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 20
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 20
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 241000008904 Betacoronavirus Species 0.000 claims description 12
- 208000001528 Coronaviridae Infections Diseases 0.000 claims description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 6
- 206010047249 Venous thrombosis Diseases 0.000 claims description 6
- 206010052015 cytokine release syndrome Diseases 0.000 claims description 6
- 239000013589 supplement Substances 0.000 claims description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 5
- 229930003268 Vitamin C Natural products 0.000 claims description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 5
- 235000019154 vitamin C Nutrition 0.000 claims description 5
- 239000011718 vitamin C Substances 0.000 claims description 5
- 239000011701 zinc Substances 0.000 claims description 5
- 229910052725 zinc Inorganic materials 0.000 claims description 5
- 235000016804 zinc Nutrition 0.000 claims description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 4
- 229930003270 Vitamin B Natural products 0.000 claims description 4
- 229930003316 Vitamin D Natural products 0.000 claims description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 4
- 235000021321 essential mineral Nutrition 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 235000019155 vitamin A Nutrition 0.000 claims description 4
- 239000011719 vitamin A Substances 0.000 claims description 4
- 235000019156 vitamin B Nutrition 0.000 claims description 4
- 239000011720 vitamin B Substances 0.000 claims description 4
- 235000019166 vitamin D Nutrition 0.000 claims description 4
- 239000011710 vitamin D Substances 0.000 claims description 4
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 4
- 229940045997 vitamin a Drugs 0.000 claims description 4
- 229940046008 vitamin d Drugs 0.000 claims description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
- 208000025721 COVID-19 Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 206010012218 Delirium Diseases 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 208000037847 SARS-CoV-2-infection Diseases 0.000 claims description 3
- 239000012752 auxiliary agent Substances 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 230000000977 initiatory effect Effects 0.000 claims description 3
- 208000028774 intestinal disease Diseases 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- 230000000153 supplemental effect Effects 0.000 claims description 3
- 241000709661 Enterovirus Species 0.000 claims description 2
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- 208000015294 blood coagulation disease Diseases 0.000 claims description 2
- 208000015114 central nervous system disease Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 13
- 239000003814 drug Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 3
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063074602P | 2020-09-04 | 2020-09-04 | |
| US63/074,602 | 2020-09-04 | ||
| US202163142669P | 2021-01-28 | 2021-01-28 | |
| US63/142,669 | 2021-01-28 | ||
| PCT/US2021/048991 WO2022051575A2 (en) | 2020-09-04 | 2021-09-03 | Compounds and methods for treating viral infection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023541007A JP2023541007A (ja) | 2023-09-27 |
| JPWO2022051575A5 true JPWO2022051575A5 (https=) | 2024-09-12 |
| JP2023541007A5 JP2023541007A5 (https=) | 2024-09-12 |
Family
ID=80491477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023515155A Pending JP2023541007A (ja) | 2020-09-04 | 2021-09-03 | ウイルス感染処置のための化合物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230346816A1 (https=) |
| EP (1) | EP4208137A4 (https=) |
| JP (1) | JP2023541007A (https=) |
| CA (1) | CA3194024A1 (https=) |
| MX (1) | MX2023002667A (https=) |
| TW (1) | TW202228730A (https=) |
| WO (1) | WO2022051575A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202239417A (zh) * | 2021-01-29 | 2022-10-16 | 艾米爾 Ｅ 哈森 | 預防病毒感染之方法 |
| CA3256512A1 (en) * | 2022-04-21 | 2023-10-26 | Therapeutikos, Inc. | METHODS OF TREATING INFLAMMATION |
| GB2628963A (en) * | 2023-02-08 | 2024-10-16 | Univ Of Lincoln | Formulations and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1533776A (zh) * | 2003-03-27 | 2004-10-06 | 中国人民解放军第三军医大学 | N-乙酰氨基葡萄糖在制备用于治疗病毒或细菌感染所致的局部损伤和全身症状的药物中的应用 |
| AU2006249771A1 (en) * | 2005-05-24 | 2006-11-30 | Wellgen, Inc. | Compositions and methods for the prevention and treatment of conditions associated with inflammation |
| WO2011046057A1 (ja) * | 2009-10-15 | 2011-04-21 | 独立行政法人産業技術総合研究所 | シアリルラクトサミン系、シアリルルイスx系のシアル酸とフコース含有新規糖鎖化合物 |
| JP5807895B2 (ja) * | 2011-02-17 | 2015-11-10 | 学校法人慶應義塾 | Ｈｃｖｒｎａ複製抑制剤 |
| NZ732118A (en) * | 2011-04-15 | 2018-11-30 | Marine Polymer Tech Inc | Treatment of disease with poly-n-acetylglucosamine nanofibers |
| CN107281199A (zh) * | 2017-07-27 | 2017-10-24 | 吉林省始祖生物波医学研究院有限公司 | N‑乙酰‑d‑氨基葡萄糖及其药物可接受盐在制备治疗病毒性肝炎药物中的应用及药物 |
-
2021
- 2021-09-03 TW TW110132929A patent/TW202228730A/zh unknown
- 2021-09-03 MX MX2023002667A patent/MX2023002667A/es unknown
- 2021-09-03 US US18/024,399 patent/US20230346816A1/en active Pending
- 2021-09-03 CA CA3194024A patent/CA3194024A1/en active Pending
- 2021-09-03 JP JP2023515155A patent/JP2023541007A/ja active Pending
- 2021-09-03 EP EP21865159.4A patent/EP4208137A4/en active Pending
- 2021-09-03 WO PCT/US2021/048991 patent/WO2022051575A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101653071B1 (ko) | 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생 | |
| Lehmann et al. | Chlorpromazine: new inhibiting agent for psychomotor excitement and manic states | |
| EP1001760B1 (en) | Composition for controlling mood disorders in healthy individuals | |
| Steiner et al. | Guillain‐Barré syndrome after epidural anesthesia: direct nerve root damage may trigger disease | |
| Chakrabarti et al. | Reduction of platelet stickiness by phenformin plus ethyloestrenol | |
| EP4520394A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| JP2025148449A5 (https=) | ||
| Rukma | Glucagon for refractory anaphylaxis | |
| Wells et al. | ECT-induced asystole from a sub-convulsive shock | |
| Park et al. | Successful treatment of propofol-related infusion syndrome in critically ill patient receiving low-dose propofol infusion: a case report | |
| JPWO2022051575A5 (https=) | ||
| HUT56496A (en) | Process for producing pharmaceutical compositions comprising buspirone, suitable for treating apnoea arising during sleep | |
| JPWO2019232130A5 (https=) | ||
| Daley et al. | Another hypotensive agent—methyldopa | |
| CN108472375A (zh) | 中重度流感的治疗方法 | |
| JP3227578B2 (ja) | 睡眠誘起性無呼吸症治療剤 | |
| CN109464441B (zh) | 3-乙酰氨基香豆素在制备治疗或预防高尿酸血症及肾损伤的药物中的应用 | |
| EP4132485B1 (en) | Phenol for use in the treatment of coronavirus induced dyspnoea | |
| Dorsey | Venoarterial bypass in hypothermia | |
| JP2021509671A5 (https=) | ||
| Marshall | Tricyclic overdose | |
| Chander et al. | Adriamycin induced pulseless electrical activity and cardiovascular collapse during general anesthesia for ventriculo-peritoneal shunt insertion | |
| JP6838676B2 (ja) | 頻脈性不整脈の処置用の医薬組成物 | |
| RU2457834C1 (ru) | Способ лечения метаболического синдрома | |
| Yamasaki et al. | Oral surgery under general anesthesia in a patient with catecholaminergic polymorphic ventricular tachycardia: A case report |